Arrowhead Pharmaceuticals, Inc. (ARWR)

US — Healthcare Sector
Peers: WVE  CTMX  ASMB  NLTX  BMRN  INCY  IONS  APLS  PRQR  ANNX  DAWN  TERN  MRTX  AMLX  ISEE  BPMC  KRTX 

Automate Your Wheel Strategy on ARWR

With Tiblio's Option Bot, you can configure your own wheel strategy including ARWR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ARWR
  • Rev/Share 4.0882
  • Book/Share 5.1305
  • PB 3.0485
  • Debt/Equity 0.0
  • CurrentRatio 4.2921
  • ROIC -0.8454

 

  • MktCap 2157122000.0
  • FreeCF/Share -4.2861
  • PFCF -3.7738
  • PE -14.2144
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.4683

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
ARWR
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an.

Read More
image for news Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
ARWR
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive

Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.

Read More
image for news Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
ARWR
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.

Read More
image for news Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

About Arrowhead Pharmaceuticals, Inc. (ARWR)

  • IPO Date 1993-12-16
  • Website https://arrowheadpharma.com
  • Industry Biotechnology
  • CEO Dr. Christopher R. Anzalone Ph.D.
  • Employees 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.